HB 513 — Distributing Pharmaceutical Drugs and Devices
by Rep. Rommel (CS/SB 1252 by Health Policy Committee and Senator Passidomo)
This summary is provided for information only and does not represent the opinion of any Senator, Senate Officer, or Senate Office.
Prepared by: Health Policy Committee (HP)
HB 513 exempts the third-party logistics providers of prescription drug manufacturers from the requirements of ch. 465, F.S., (related to pharmacy) to the extent the third-party logistics provider is engaged in the manufacture or distribution of certain dialysate, drugs, or devices necessary to perform home renal dialysis on patients with chronic kidney failure.
The bill also clarifies that the current law exemption applies to a prescription drug manufacturer to the extent the manufacturer is engaged in the manufacture or distribution of such dialysate, drugs, or devices and no longer requires that the manufacturer be solely engaged in such activity in order to qualify for the exemption.
If approved by the Governor, these provisions take effect July 1, 2018.
Vote: Senate 36-0; House 114-0